Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.

MLA

Therkelsen, Kate Elizabeth, et al. “Long-Term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.” Neurology, vol. 101, no. 7, Aug. 2023, pp. e710–16. EBSCOhost, https://doi.org/10.1212/WNL.0000000000207490.

APA

Therkelsen, K. E., Schaff, L. R., Nandakumar, S., Omuro, A. M. P., DeAngelis, L. M., & Grommes, C. (2023). Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant. Neurology, 101(7), e710–e716. https://doi.org/10.1212/WNL.0000000000207490

Chicago

Therkelsen, Kate Elizabeth, Lauren R Schaff, Subhiksha Nandakumar, Antonio M P Omuro, Lisa M DeAngelis, and Christian Grommes. 2023. “Long-Term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant.” Neurology 101 (7): e710–16. doi:10.1212/WNL.0000000000207490.